|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
|
3.8 Prévention - Alimentation
|
|
|
Eating organic food linked with lower cancer risk [NHS Choices]
|
|
|
|
|
|
There
was a notable difference in sociodemographics and lifestyles of those
eating the most organic food. The researchers tried to adjust for these
factors, but there's still a chance these things influenced the results.
This means the study can't prove that eating organic food is
responsible for the reduced risk – it could just be down to living a
healthier lifestyle in general.
|
|
|
|
|
|
|
No, Organic Food Doesn't Reduce Cancer Risk. That's Biologically Impossible [ACSH]
|
|
|
|
|
|
Of
the study's participants, 78% were female, so the data are skewed by
gender. The data were also collected using questionnaires, which is an
incredibly unreliable way to do research. The authors' ability to
properly control for all confounders was unconvincing. And the authors
didn't even attempt to collect data on pesticide exposure. (So, what
exactly were they measuring?)
|
|
|
|
|
|
|
Organic foods tied to slightly lower cancer risk [Reuters]
|
|
|
|
|
|
Compared
to people who consumed the least amount of organic foods, people who
consumed the most were 25 percent less likely to develop cancer during
the study. In absolute terms, this translated into about a 0.6 percent
lower risk of cancer.
|
|
|
|
|
|
|
Organic Foods for Cancer Prevention—Worth the Investment? [JAMA Internal Medicine]
|
|
|
|
|
|
While
the study by Baudry et al has several notable strengths, such as its
large sample size, prospective design, and modest loss to follow-up, it
also has significant weaknesses, which mandate careful interpretation of
the findings. Most salient among the weaknesses is the fact that the
organic food questionnaire was not validated; therefore, it is unclear
what the intended exposure, organic food consumption, was actually
measuring.
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
Bristol-Myers' Opdivo-Yervoy combo hits a regulatory snag in lung cancer [FiercePharma]
|
|
|
|
|
|
On
Friday, the New Jersey drugmaker disclosed that EU regulators had
requested more survival data from its Checkmate-227 trial, which is
evaluating the duo in previously untreated lung cancer. And while the
company has already submitted a new analysis, it’s now facing a
regulatory slowdown. The FDA pushed back its decision date by three
months, and now expects to hand down a verdict by May 20 of next year.
|
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.6 ESMO
|
|
|
|
|
5.6.6.1 ESMO - Sein (triple négatif)
|
|
|
|
5.6.6.3 ESMO - Sein (palbociclib)
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
|
6.12 Ethique
|
|
|
|
6.13 Soins palliatifs
|
|
|
|
6.5 Médecines alternatives/complémentaires
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|